No more public speaking for JL, both the Jeffries presentation and this one were much better than any JL presentations. Leave JL in SD, or send him to the Alps!
yes, not a good start, but is holding up well under the pressure. JL would have said ah and um 50 each times by now.
Agree with letter A) under Reg FD, the company should put out a press release for any significant news. Don't expect any if JL is talking. You might hear some snoring from the audience, JL is one boring speaker.
MD's don't need to read consumer reports, they already know everything, just ask them. The consumer reports article was a win, or smart ploy for shorts to slow consumer demand and investor interest, but will have little long term effect. Bought my calls back, long only again. Man I hate this stock!
I called in once on ZGEN. Cramer liked it at $20, when I called it was $7-8 and he said don't buy. He was right for a period this time, it went lower to the $4's and below. I loaded up and one day, BMS acquired for $9.75, thank you Jesus, that was a big blessing! Cramer has a mixed record in biotech, he's called a few big winners and missed on a few. He does not know enough about the science of biotech, just says what he hears from others and sometimes I think he hears well. Some CEO's use him for pump priming before a secondary.
thanks Fib, it's good to hear you are still with us. It's been slow on the IMGN MB and with the stock price/volume. Not much new interest it seems. I ran into a key person who seemed excited about another new compound entering the clinic this year, maybe we will hear more about that soon, not that a new molecule will have much effect on the stock price.
Shorts are controlling the message, manipulating the media to focus on the mean/average, placebo adjusted weight loss when ARNA should be focusing the message on the responder weight loss numbers. ARNA execs are failing and the shareholders are paying for their failure. They really don't seem to get that shorts are out to destroy the company and they are in a death match where only one will survive. They need to up their game and I am not sure they are capable. BOD is not engaged, JL thinks he is running his own private company, man this is a time sucker!!!
VPHM acquisition potential could draw some new interest and capital to TSRX, they have an anti-bacterial medication. If acquired, $2BB in biopharma investment $, will need to find a new home, unless it's a stock for stock transaction with another antibiotic company and people decide to hold. A potential catalyst to watch.
If ARNA execs could communicate better this would not still be an issue. I amd others told them a long time ago, to change the focus of their communication to responders and non-responders, but they have failed to control the conversation and let shorts define efficacy. Shorts are out to destroy and ARNA execs are in love with self enrichment in the form of low-priced option awards, so the investors, who own the company get the screws.
disagree, I think the initial script numbers will be fine, maybe even good. I think the selling is related to managements excessive greed. The stock started declining when the S8 was filed. It might be conicidence, but it's getting old. This is a public company, not Jack Leif and friend's private company. The BOD needs to reing in the excesses.
Not sure I like this idea, why should ACAD, a winner tie in with ARNA, the loser. If they could fire the terrible ARNA execs and stop the excessive greed and dilution, it might make sense. I sold the $8 calls to try and exit this declining POS, so there's no upside potential for me in this proposal, I vote against it.
well, I bought at $2, never heard of KNDI, will check it out. I like TSRX and IMGN, but wait until afternoon to buy IMGN, it always fades shortly after the open and usually rallies on the close. TSRX has 50% upside, probably not 2-4x like some ther bios, but less risk based on strong phase III trials.
agree that ARNA exect like to reward themselves with copiuos free shares and cheap options. They are certainly making every effort to help the shorts by diluting shareholders and with poor communications. I thought my large call sale on Friday would have boosted the short term price, but I guess I had no effect. Ready to exit from this time sucking drama stock.
Another signal that IMGN is highly undervalued, Aragon acquired for $650MM based on a drug in phase II for PC and earlier development for BC. IMGN's business execs fails to deliver full market value for IMGN shareholders. If this continues for much longer, the solutions are an acquisition, or removal and replacement of said failing execs.
yep, getting tired of the drama and lost time with no financial benefit. I hown and know about other stocks that go up, at least more than they go down!
I can't believe people are so lacking in knowledge, these are grants to Directors with a zero cost basis, free shares, $100K for a few meetings. Nice deal if you can get it.